v3.25.1

Trade and other liabilities and other non-current liabilities | 12 Months Ended
--- | ---
Dec. 31, 2024
Trade and other liabilities and other non-current liabilities |
Trade and other liabilities and other non-current liabilities | 26. Trade and other liabilities and other non-current liabilities ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31,
​ |  | 2024 |  | 2023
​ | ​ | (Euro, in thousands)
Trade and other liabilities | ​ | € | 97,780 | ​ | € | 134,653
Current financial instruments | ​ | ​ | 5 | ​ | ​ | —
Accrued charges | ​ | ​ | 1,092 | ​ | ​ | 548
Total trade and other liabilities | ​ | € | 98,877 | ​ | € | 135,201
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Non-current contingent consideration related to milestones CellPoint | ​ | € | 20,576 | ​ | € | 20,972
Other non-current liabilities | ​ | ​ | 13,245 | ​ | ​ | 10,598
Total other non-current liabilities | ​ | € | 33,821 | ​ | € | 31,570
​ ​ The carrying value of trade and other liabilities approximates their fair value. The contingent consideration arrangement relating to the acquisition of CellPoint requires us to pay the former owners of CellPoint additional considerations up to €100.0 million. This amount is due when certain sequential development (€20.0 million), regulatory (€30.0 million) and sales-based (€50.0 million) milestones would be achieved. Total fair value at acquisition date of these milestones amounted to €20.2 million at acquisition date. The fair value measurement is based on significant inputs that are not observable in the market, which are classified as Level 3 inputs. Key assumptions in the valuation at December 31, 2022 included a discount rate of 12.5%, an appropriate probability of success of reaching these milestones and expected timing of these milestones, in line with the timelines and probabilities used in our impairment test of the CAR-T business. As per December 31, 2024 changes were made to the discount rate (1 3.75% at December 31, 2024 and 13.72% at December 31, 2023) and the expected timing of the milestones. The only impact that was recognized compared to the date of acquisition is the discounting effect. This is recognized on the line “other financial income”. A change in probabilities of success by 5 percentage points would result in a change of €2.9 million in the total contingent consideration liability on December 31, 2024. A change in the applied discount rate by 1 percentage point would result in a change of €0.6 million in the total contingent consideration liability on December 31, 2024. A delay of one year in expected timing of the milestones would result in a decrease of €2.5 million in the total contingent consideration liability on December 31, 2024.

X
- Definition Represents information pertaining to Trade and other liabilities and other non-current liabilities. + References No definition available. + Details
Name: | glpg_TradeAndOtherLiabilitiesAndOtherNonCurrentLiabilitiesAbstract
Namespace Prefix: | glpg_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of trade and other payables. [Refer: Trade and other payables] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 10 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration